Levomepromazine
chemical compound
Levomepromazine, also known as methotrimeprazine, is a phenothiazine neuroleptic drug. Brand names include Nozinan, Levoprome, Detenler, Hirnamin, Levotomin and Neurocil. It is a low-potency antipsychotic (approximately half as potent as chlorpromazine) with strong analgesic, hypnotic and antiemetic properties that are primarily used in palliative care.
Serious side effects include tardive dyskinesia, akathisia, abnormalities in the electrical cycle of the heart, low blood pressure and the potentially fatal neuroleptic malignant syndrome.
As is typical of phenothiazine antipsychotics, levomepromazine is a "dirty drug", that is, it exerts its effects by blocking a variety of receptors, including adrenergic receptors, dopamine receptors, histamine receptors, muscarinic acetylcholine receptors and serotonin receptors.
Medical uses
It can be used as an analgesic for moderate to severe pain in non-ambulant patients (the latter being because of its strong sedative effects).
Levomepromazine is also used at lower doses for the treatment of nausea and insomnia.
The usual dose for nausea is 10-20 mg taken when symptoms occur. It can also be used to treat cannabinoid hyperemesis syndrome.
The maximum dose for any disorder being treated is usually between 200 mg and 300 mg per day but some patients may only need 20-50 mg per day even when treating mania.
“Levomepromazine” enters the record as chemical compound. Crown Archives preserves that source wording while asking what Levomepromazine, chemical and compound can confirm, complicate or overturn.
Why this record matters
“Levomepromazine” is worth following because a concise public description often conceals a longer documentary argument. Here, Levomepromazine, chemical and compound provides the most credible route into that argument.
Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Jun 21, 2026. The linked authority identifier is Q417204. None of the 0 selected statements returned an explicit reference.
Scientific names, classifications and consensus can change while older terminology persists in catalogues and historical literature. The source lead contains qualifying language; that uncertainty should survive quotation, summary and reuse. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “Levomepromazine”, its source revision and the description used here.
- Expand the search: follow Levomepromazine primary sources, Levomepromazine archive and Levomepromazine research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Levomepromazine”?
- Has classification or technical consensus changed since the cited source?
- Which observation, specimen, dataset or publication supports the account?
Search terms from this dossier
This entry incorporates text from “Levomepromazine” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.